everolimus for Neuroendocrine Tumors

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Neuroendocrine Tumors
everolimus - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the combination of LEE011 with everolimus to see if it is effective against cancer with minimal side effects.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Progression Free Survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

LEE011 and everolimus
1 of 1

Experimental Treatment

21 Total Participants · 1 Treatment Group

Primary Treatment: everolimus · No Placebo Group · Phase 2

LEE011 and everolimusExperimental Group · 2 Interventions: everolimus, LEE011 · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Everolimus
FDA approved
Ribociclib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,823 Previous Clinical Trials
584,463 Total Patients Enrolled
12 Trials studying Neuroendocrine Tumors
468 Patients Enrolled for Neuroendocrine Tumors
Dana-Farber Cancer InstituteOTHER
1,014 Previous Clinical Trials
394,323 Total Patients Enrolled
9 Trials studying Neuroendocrine Tumors
341 Patients Enrolled for Neuroendocrine Tumors
NovartisIndustry Sponsor
1,581 Previous Clinical Trials
2,702,085 Total Patients Enrolled
18 Trials studying Neuroendocrine Tumors
1,165 Patients Enrolled for Neuroendocrine Tumors
M.D. Anderson Cancer CenterOTHER
2,783 Previous Clinical Trials
1,784,837 Total Patients Enrolled
15 Trials studying Neuroendocrine Tumors
1,333 Patients Enrolled for Neuroendocrine Tumors
Diane Reidy-Lagunes, MD, MSPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.